Abeomics Competitors and Similar CompaniesClear all

Abeomics's competitors and similar companies include Centogene, CN Bio, Zafrens and NeyroblastGX.

	Abeomics Abeomics is a company that provides a drug screening platform.	Centogene Centogene is a biotechnology company that provides services in the field of genetic diagnostics for rare hereditary diseases.	CN Bio CN Bio Innovations (formerly known as Zyoxel) is a company that develops organ-on-a-chip systems for human drug discovery and preclinical research.	Zafrens Zafrens is a therapeutics company developing a platform to isolate, culture, image, and sequence cells.	NeyroblastGX NeyroblastGX is a developer of theranostic products for neurodegenerative and infectious diseases.
Founding Date	Founding Date 2013	Founding Date 2005	Founding Date 2008	Founding Date 2022	Founding Date 2020
Type	Type Private	Type Public	Type Subsidiary	Type Private	Type Private
Tags	Tags Technology bioengineering biotech drug development genetics medical diagnostics platform	Tags Technology bioengineering biotech genetics medical diagnostics platform	Tags Technology bioengineering biotech drug development medtech platform	Tags Technology bioengineering biotech drug development platform	Tags Healthcare biotech drug development genetics medical diagnostics platform
Locations	Locations San Diego, US HQ	Locations Rostock, DE HQ Wien, AT Berlin, DE Frankfurt Am Main, DE Hamburg, DE Greater Noida, IN Dubai, AE see more	Locations Milton, GB HQ	Locations San Diego, US HQ	Locations Murrieta, US HQ
Employees	Employees 3	Employees 80823% increase	Employees 576% increase	Employees 33	Employees 1
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) €48.5m (FY, 2023)	Revenue (est.) £3.5m (FY, 2024)	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods €29.1m (FY, 2023)	Cost of goods £1.4m (FY, 2024)	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit €23.7m (FY, 2023)	Gross profit £2.1m (FY, 2024)	Gross profit N/A	Gross profit N/A
Net income	Net income N/A	Net income (€35.5m) (FY, 2023)	Net income (£6.3m) (FY, 2024)	Net income N/A	Net income N/A
Funding
Total funding raised	Total funding raised N/A	Total funding raised $ 29.6m	Total funding raised $ 11.5m	Total funding raised N/A	Total funding raised N/A